

## Table of Contents

	Page
<b>1 Overview</b>	8
<b>2 Market Size of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009</b>	9
<b>3 Characteristics of Approved Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins</b>	16
<b>4 Platform Technologies for the Generation of Novel Therapeutic Antibody-based Products</b>	20
4.1 In vivo generation of antibodies	20
4.2 In vitro generation of antibodies	24
4.3 Outlook	25
<b>5 Platform Technologies for the Optimization of Novel Therapeutic Antibody-based Products</b>	28
5.1 Use of natural immunoglobulin variants	28
5.2 Mutated immunoglobulins	28
5.3 Glyco-engineering	28
5.4 Improvement of pharmaceutical quality	29
5.5 Outlook	29
<b>6 Platform Technologies for Products beyond Monoclonal Antibodies</b>	32
6.1 Oligoclonal antibodies	32
6.2 Engineering of novel antibody-based products	32
6.3 Outlook	34
<b>7 Platform Technologies for the Expression and Manufacturing of Novel Therapeutic Antibodies and Antibody-based Products</b>	40
7.1 Mammalian cells	40
7.2 Other eukaryotic systems	41
7.3 Yeast expression	42
7.4 Bacterial expression	42
7.5 Outlook	42

<b>Tables</b>		
	Table 1: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 with Source of Information	10
	Table 2: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 by Product	13
	Table 3: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 by Therapeutic Area	14
	Table 4: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 by Target	15
	Table 5: Characteristics of Approved Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins	18
	Table 6: Generation of Monoclonal Antibodies in vivo	22
	Table 7: Generation of Monoclonal Antibodies by B-cell Isolation	23
	Table 8: Generation of Monoclonal Antibodies in vitro	26
	Table 9: Generation of Monoclonal Antibodies in Cells in vitro	27
	Table 10: Modification of Monoclonal Antibodies for Function – Protein and Glyco-Engineering	30
	Table 11: Improvement of Pharmaceutical Quality of Antibodies	31
	Table 12: Oligo- and Polyclonal Antibodies	35
	Table 13: Novel Antibody-derived Formats by Protein Engineering	36
	Table 14: Chemical and Protein Conjugates of Antibodies	37
	Table 15: Automation of Antibody Lead Identification and Optimization	38
	Table 16: Antibody: Druggability, Cross-Reactivity, Target Discovery and Others	39
	Table 17: Expression and Manufacturing of Monoclonal Antibodies	45
<b>Figures</b>		
	Figure 1 Evolution of the Productivity of Mammalian Cell Culture	40
	Figure 2 Calculation of Cost Structure for a Mammalian Cell Culture Process of a Recombinant Monoclonal Antibody – part I	43
	Figure 3 Calculation of Cost Structure for a Mammalian Cell Culture Process of a Recombinant Monoclonal Antibody – part II	43
<b>ADDENDUM</b>		
<b>Company Profiles</b>		
	4-Antibody	46

Abcheck	49
Abeome	51
Ablexis	53
Ablynx	54
AdAlta	58
Adimab	60
Affimed Therapeutics	62
Affitech	65
Alder Biopharmaceuticals	69
Alligator Biosciences	72
Ambrx	74
AnaptysBio	77
Antitope	79
arGEN-X	81
Armagen Technologies	83
Avanir Pharmaceuticals	85
Avipep	87
BioAtla	89
BioInvent	92
Biolex Therapeutics	95
Biosite	97
Biotecnol	99
Bristol-Myers Squibb (Medarex)	101
Calmune	105
Cephalon (Arana Therapeutics)	107
Chiome Bioscience	109
Crescendo Biologics	111
CytomX	113
Cytos	115
Discerna	117
Dyax	119

Elusys Therapeutics	122
Emergent Biosolutions (Trubion Pharmaceuticals)	125
Epitomics & Apexigen	128
Epivax	131
Esbatech & Delenex	133
Evec	135
ExcelImmune	137
f-star	139
Ganymed Pharmaceuticals	142
Genexine	145
Genmab	147
GlaxoSmithKline (Domantis)	150
Glycotope	153
GTC Biotherapeutics	156
Immunocellular Therapeutics	159
Immunogen	161
InNexus	163
InterVexion Therapeutics	165
Johnson & Johnson (Crucell)	167
Kalo Bios	169
Kenta Biotech	172
Kolltan	174
Kyowa Hakko Kirin (BioWa)	176
Lonza	179
MabCure	182
Macrogenics	185
MAT Biopharma	188
Merck & Co (GlycoFi)	190
Merrimack Pharmaceuticals	192
Merus	195

Micromet	198
Millegen	202
Morphosys	204
Morphotek	207
MSM Protein Technologies	210
Nascent Biologics	212
Neurimmune	213
North Coast Biologics	215
Open Monoclonal Technology (OMT)	218
OriGene Technologies	220
Oxford Biotherapeutics	222
Patrys	224
Pepscan Therapeutics	227
Pfizer (CovX)	229
Philogen	232
Planet Biotechnology	235
Regeneron	237
Sea Lane Biotechnologies	242
Seattle Genetics	244
Sloning Biotechnology	247
Sorrento Therapeutics	249
Symphogen	251
Synageva	254
Syntarga	256
Theraclone	259
Trellis	261
TRION Pharma	264
Vaccinex	267
Vivalis	269
Viventia Biotechnologies	271
XBiotech	274

Xencor	276
XOMA	279
Xori	282